Project Grant R44HD084019

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project grant, awarded to Anvil Diagnostics Inc. in the amount of $298,646, aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples using digital PCR hardware. The proposed technology seeks to comprehensively identify and quantify a panel of 17 common sepsis-causing pathogens within 4 hours from small blood volumes,...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...

The National Science Foundation (NSF) awarded a $1,250,000 Cooperative Agreement under its Technology, Innovation, and Partnerships (CFDA 47.084) program to Prompt Diagnostics, Inc., a for-profit manufacturer of advanced diagnostic technologies. The funding supports the development of an automated, all-in-one diagnostic platform for rapid detection and characterization of Treponema pallidum, the bacterium that causes syphilis. The project aims to create a portable, point-of-care device that...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The platform will isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes, enabling clinicians to quickly determine appropriate targeted...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to reduce overtreatment and prevent emerging antibiotic resistance. In Phase I, the company will develop viability PCR (V-PCR) assays for Chlamydia trachomatis and Neisseria...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,362 to RT Microdx Inc. focuses on developing a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for use by non-healthcare professionals in non-clinical settings, enabling rapid and reliable pathogen detection at home. Key technical objectives include optimizing the platform's...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000 to Resonantia Diagnostics, Inc. to develop a rapid diagnostic platform for identifying pathogens and determining antimicrobial susceptibility within 60 minutes. The project aims to advance an acoustic sensor-based technology that can accurately detect pathogens at low concentrations and test their susceptibility to a diverse range of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $881,303 to The Children's Hospital of Philadelphia (CHOP) to conduct high-resolution, whole genome tracking of pathogen transmission and infection in the neonatal intensive care unit (NICU). The key objectives are to use whole genome sequencing and diagnostic allele surveillance to determine bacterial transmission and...

Chosen Diagnostics Inc., a minority-owned, woman-owned small business, has been awarded a $999,749 Cooperative Agreement from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program. The funding will support the development of reagents and reference standards for an innovative diagnostic test to quantify host biomolecules related to gut health in premature infants. This work aims to enable early and accurate detection of necrotizing enterocolitis...

This Project Grant award of $3,055,197.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and evaluation of a rapid, low-cost phenotypic test for the detection of carbapenemase-producing organisms (CPOs). The objective is to create a structurally-programmed sticker microfluidic test that can provide rapid, objective carbapenemase detection and distinguish between carbapenemase...